Clinical Trial Detail

NCT ID NCT04092283
Title Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Paclitaxel

Cisplatin + Etoposide

Cisplatin + Durvalumab + Etoposide

Carboplatin + Durvalumab + Paclitaxel

Durvalumab

Cisplatin + Durvalumab + Pemetrexed Disodium

Cisplatin + Pemetrexed Disodium

Age Groups: adult senior

No variant requirements are available.